START collaborates with Sarah Cannon to accelerate Phase I drug development programs

Sarah Cannon Research Institute and South Texas Research Accelerated Therapeutics moved to collaborate ensuring augmenting their globally acclaimed phase I drug development programs therefore attaining peak efficiency in enrollment and quality of their clinical research programs. Both the companies have forte and finesse for conducting oncology Clinical Trials.

Lon Smith, MD, President and CEO of South Texas Oncology and Hematology, PLLC (STOH) and Manager of START. “Under the leadership of Dr. Patnaik, Dr. Papadopoulos and Dr. Rasco, we look forward to further growing our clinical research initiatives in partnership with a global research network.”

START has enrolled more than 6,000 patients onto phase I clinical trials with more than 900 enrolled in 2017. Currently, START’s strategic sites included in the collaboration are located in San Antonio, Texas, Grand Rapids, Michigan, and Madrid, Spain. Sarah Cannon on the other hand has been a clinical trial leader in the majority of approved therapies over the last decade, enrolling more than 3,000 patients on trials each year and conducting more than 360 first-in-human studies. Their partnership signifies advancement of drug development ensuring access to anticancer agents.

Image Source: Sarah Cannon Research Institute